2005 News Releases

Dec 28, 2005 - Stock Options Granted
Dec 23, 2005 - Negotiations with Debenture Holders Finalized
Dec 20, 2005 - Tectin Phase IIb/III Interim Analysis Expected
Dec 20, 2005 - Wex Names New CEO and Strengthens Management Team
Dec 19, 2005 - New Director
Dec 09, 2005 - Special Meeting of Shareholders
Nov 23, 2005 - WEX Requests Patent Re-examination
Nov 17, 2005 - Chief Financial Officer Resigns
Nov 15, 2005 - Second Quarter Results
Nov 09, 2005 - WEX receives positive response from FDA
Oct 06, 2005 - Tectin Chinese Phase IIa Preliminary Results
Sep 27, 2005 - Restructuring
Sep 19, 2005 - Departure of Chief Operating Officer
Aug 25, 2005 - WEX Completes Investigators' Meeting
Aug 24, 2005 - WEX to Present Two Posters at the 11th World Congress on Pain
Aug 18, 2005 - Results of the Phase IIa Opioid Withdrawal Study
Aug 17, 2005 - Appointment of Interim Chief Financial Officer
Aug 16, 2005 - WEX Seeks a New CEO
Aug 15, 2005 - Annual and Special Meeting Update
Aug 15, 2005 - First Quarter Results
Aug 10, 2005 - Debenture Redemption Request and Negotiations
Jul 13, 2005 - Expiry Dates for Warrants Extended
Jul 06, 2005 - Shareholders Rights Plan Adoptedul 06, 2005 - Shareholders R
Jun 29, 2005 - Year End Financial Results
Jun 28, 2005 - Patent No. ZL95190556.2
Jun 02, 2005 - Protocol Amendment Approved by Health Canada
May 26, 2005 - New Director of Intellectual Property
May 05, 2005 - Departure of General Manager
Apr 18, 2005 - New Director and Chariman of the Board Appointed
Apr 07, 2005 - WEX Receives €2,000,000 from Co-Development Partner
Mar 16, 2005 - Collaboration Between ESTEVE and WEX Grows to Co-Development
Mar 09, 2005 - Appointment of Chief Medical Officer
Feb 14, 2005 - Financial Results for Third Quarter Ended December 31, 2004
Feb 07, 2005 - Appointment of Chief Financial Officer
Jan 04, 2005 - Wex Completes Tetrodin™ Trial Enrollment

< 2004 news